

General description

Mercaptopurine is a purine antimetabolite antineoplastic agent used in treatment protocols for various leukaemias and lymphomas.

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| INN                | Mercaptopurine                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| ATC codes          | L01BB02                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Medicine type      | Chemical agent                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| EML status history | First added in 1984 (TRS 722) for Unspecified malignant neoplasms of ill-defined or unspecified sites<br>Added in 2015 (TRS 994) for Lymphoid leukaemia, not elsewhere classified<br>Added in 2015 (TRS 994) for Acute myeloid leukaemia with recurrent genetic abnormalities<br>Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites<br>Added in 2023 (TRS 1049) for Langerhans cell histiocytosis |
| Wikipedia          | <a href="#">Mercaptopurine</a>                                                                                                                                                                                                                                                                                                                                  |
| DrugBank           | <a href="#">Mercaptopurine</a>                                                                                                                                                                                                                                                                                                                                  |

Recommendations

Section      Cytotoxic medicines

Oral > Liquid: 20 mg per mL  
Oral > Solid: 50 mg tablet

Indications

- Lymphoid leukaemia, not elsewhere classified
- Acute myeloid leukaemia with recurrent genetic abnormalities
- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Langerhans cell histiocytosis

